Comparison of laboratory characteristics and clinical prognosis of APL with negative and positive PML-RARα gene.

This study analyzes the laboratory characteristics and prognosis of patients between PML-RARα negative APL and PML-RARα positive APL and compares the differences in order to improve the understanding of this rare APL and guide clinical diagnosis and treatment. A total of 81 patients with newly diagnosed APL based on bone marrow cell morphology were included, with 14 in the PML-RARα gene negative group and 67 in the PML-RARα gene positive group. The sex, age, peripheral blood routine test, coagulation related indicators, bone marrow cell morphology, flow cytometric immunophenotype, abnormal chromosome expression and prognosis of the 2 groups were analyzed and compared. PML-RARα gene-negative and PML-RARα gene-positive groups were statistically significant in leukocyte count, fibrinogen content, proportion of abnormal promyelocytes, positive rate of Auer bodies, strongly positive peroxidase staining, positive CD13, CD4, CD11b, CD15, CD25 expression and complete response rate during 1 course (P < .05). By the end of follow-up in February 2021, the duration of CR in the PML-RARα gene-negative group was short (P < .05). This study found that the efficacy and prognosis of patients with PML-RARα gene negative were worse than those of the positive group, but the correlation between indicators and prognosis needs to be further explored and confirmed in more diverse samples.